An Observational Study Investigating the Safety and Effectiveness of Repaglinide in Chinese Patients

NCT01077570 · clinicaltrials.gov ↗

COMPLETED

Status

2033

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

DRUG: repaglinide

Sponsor

Novo Nordisk A/S